Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG
Phase 3
Active, not recruiting
- Conditions
- Phosphomannomutase 2 DeficiencyPhosphomannomutase 2 Congenital Disorder of GlycosylationPhosphomannomutase II Congenital Disorder of GlycosylationPhosphomannomutase II DeficiencyPmm2-CDG
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Maggie's Pearl, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT04925960
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
News
No news found